Oppenheimer’s Christopher Liu and Cantor’s William Tanner see potential in Synergy’s Trulance, even if its momentum is not full steam ahead just yet.
There’s a new FDA-approved IBS-C medication on the scene. Today, the U.
Canaccord’s John Newman finds SGYP’s Trulance commercial potential enticing down the line against its competitors.
Now that SGYP has won over FDA approval in a new indication (IBS-C), did the biotech company’s competitive edge just get sharper?
H.C.
